IDiyas

For the Inventor, By the Inventor

Mountain View, CA, United States of America

Amunix Operating Inc.


USPTO Granted Patents = 24



Trademarks = 1

Forward Citations = 531

Loading Chart...
Loading Chart...

46 inventors (with patents filed for the assignee):

goldMedal Volker Schellenberger (24 out of 66 patents)

silverMedal Willem P Stemmer (21 out of 40 patents)

bronzeMedal Chia-wei Wang (21 out of 25 patents)

4.  Joshua A Silverman (17 out of 56 patents)

5.  Nathan C Geething (16 out of 20 patents)

6.  Benjamin Spink (11 out of 15 patents)

7.  Jeffrey L Cleland (10 out of 47 patents)

8.  Wayne To (7 out of 18 patents)

9.  Mikhail Popkov (4 out of 11 patents)

10.  Michael D Scholle (4 out of 5 patents)

11.  Nathaniel C Gordon (4 out of 7 patents)

12.  Andreas Crameri (4 out of 23 patents)

13.  Bryant McLaughlin (2 out of 3 patents)

14.  David Bruce Baldwin (1 out of 6 patents)

15.  John Michael Beals (1 out of 9 patents)


24 patents:

1. 10172953 - XTEN conjugate compositions and methods of making same (2019-01-08),
2. 10035839 - Blood glucose lowering compound (2018-07-31),
3. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),
4. 9976166 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2018-05-22),
5. 9938331 - Biologically active proteins having increased in vivo and/or in vitro stability (2018-04-10),
6. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),
7. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),
8. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),
9. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),
10. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),
11. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),
12. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),
13. 9168312 - Growth hormone polypeptides and methods of making and using same (2015-10-27),
14. 9062299 - Coagulation factor IX compositions and methods of making and using same (2015-06-23),
15. 8957021 - Glucose-regulating polypeptides and methods of making and using same (2015-02-17),
Amunix Operating Inc. is a biopharmaceutical company focused on the development of novel protein therapeutics using its proprietary XTEN technology. The company's platform allows for the creation of long-acting, biologically active proteins that have the potential to improve the treatment of various diseases. Amunix's therapies have the ability to enhance the duration, efficacy, and safety of protein-based drugs. With a dedicated team of experts, Amunix is committed to advancing innovative medicines to address unmet medical needs.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

24 Patents

#110 in Mountain View, CA

#3,169 in California

#13,395 in US

#25,814 in the World

...
Mountain View, CA, United States of America

Amunix Operating Inc.

Forward Citations = 531

46 inventors:

goldMedal Volker Schellenberger (24 out of 66 patents)

silverMedal Willem P Stemmer (21 out of 40 patents)

bronzeMedal Chia-wei Wang (21 out of 25 patents)

4.  Joshua A Silverman (17 out of 56 patents)

5.  Nathan C Geething (16 out of 20 patents)

Please report any incorrect information to support@idiyas.com
Loading…